Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BPR1-J097 是新型的、强效的FLT3抑制剂 (IC50:11 nM)。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 786 | 现货 | ||
25 mg | ¥ 2,484 | 现货 | ||
50 mg | ¥ 3,730 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 996 | 现货 |
产品描述 | BPR1J-097) is a novel FLT-3 inhibitor(IC50: 11±7 nM) with promising in vivo anti-tumor activities. It also inhibits FLT-3 D835Y (IC50: 3 nM). |
靶点活性 | FLT-3 D835Y:3 nM, FLT-3:11±7 nM |
激酶实验 | Kinase assays: To assay Plk1 and Aurora A kinase activity, cells are lysed after 13 hrs release in the presence of SBE13 after double thymidine block, and kinases are immunoprecipitated from lysates using antibodies as described. In brief, for each immunoprecipitation 800 μg of total protein were incubated with 1.5 μg Plk1 antibody cocktail, 3 μg Plk2 antibody, 3 μg Plk3 antibody, or 5 μg Aurora A antibody, respectively, for 2 hrs at 4°C on a rotator. Immunoprecipitated protein is collected using Protein G Agarose beads. The Plk1, Plk2 and Plk3 immunoprecipitates are incubated with 1 μg casein and with 1 μCi of [γ32-P]ATP for 30 min at 37°C in kinase buffer. The Aurora A immunoprecipitates are incubated with 0.5 μl Histone and with 1 μCi of [γ32-P]ATP for 60 min at room temperature in kinase buffer. Products from the kinase assays are fractionated on 10% Bis-Tris-polyacrylamide gels, and the phosphorylated substrate is visualized by autoradiography after an exposure of 12 to 36 hrs. An equal amount of immunoprecipitates is subjected to western blot analysis to confirm equal loading of Plk1, Plk2, Plk3 or Aurora A protein in kinase reactions. Immunoprecipitated Plk1 after 13 hrs release in the presence of SBE13 is assayed after de-phosphorylation using λ protein phosphatase and compared to kinase activity of endogenous immunoprecipitated Plk1. Activity of Plk1 kinase with and wiiiuithout de-phosphorylation is compared and the ratio between de-phosphorylated and "normal" endogenous immunoprecipitated Plk1 kinase activity is calculated. |
别名 | BPR1J097 |
分子量 | 516.61 |
分子式 | C27H28N6O3S |
CAS No. | 1327167-19-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 11 mg/mL (21.29 mM), Sonification is recommended
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.9357 mL | 9.6785 mL | 19.357 mL | 48.3924 mL |
5 mM | 0.3871 mL | 1.9357 mL | 3.8714 mL | 9.6785 mL | |
10 mM | 0.1936 mL | 0.9678 mL | 1.9357 mL | 4.8392 mL | |
20 mM | 0.0968 mL | 0.4839 mL | 0.9678 mL | 2.4196 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
BPR1J-097 1327167-19-0 Angiogenesis Tyrosine Kinase/Adaptors FLT CD135 Fms like tyrosine kinase 3 BPR-1J-097 FLT3 BPR1J097 Cluster of differentiation antigen 135 inhibit BPR1J 097 Inhibitor inhibitor